德美化工(002054.SZ):擬以不超1.3億元與晟景私募、至尚資管等共設佛山晟景二期
格隆匯8月23日丨德美化工(002054.SZ)公佈,公司為推進戰略發展,加強產融結合,落實公司戰略佈局,公司擬作為有限合夥人,擬以自有資金不超過1.3億人民幣與廣東晟景私募基金管理有限公司(“晟景私募”)、廣東至尚資產管理有限公司(“至尚資管”)等合作方共同發起設立佛山晟景二期股權投資合夥企業(有限合夥)(暫定名,以最終工商登記核准為準,“基金”)。基金的組織形式為有限合夥企業,規模不少於2億元人民幣,各合作方均以貨幣方式出資,投資方向主要為新材料、生物技術產業、能源材料、高端裝備等,同時兼顧其他新興產業領域投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.